



Tests you can trust

**Name** : Manasa Anupa (28Y/F)

**Date** : 14 Jan 2025

**Test Asked** : T3-T4-Ustsh, Quadruple Marker Second Trimester 14-22 Week

**Report Status:** Complete Report



**First National Diagnostic Chain** to have  
100% of its Labs with NABL Accreditation<sup>#</sup>



Temperature-  
Controlled  
Sample Logistics



Unique Barcode  
Tracking



Fully Automated  
Machines Inspected  
Daily



Abnormal Values  
Re-Checked Twice



Reports Verified By Expert  
MD Pathologists Stationed  
at Every Lab



**Your reports are digitally verifiable**

Scan the QR code inside the report to check authenticity  
of reported values

QR code will remain active for 30 days from report release date

Accredited by



NABL From 2005



ISO 9001: 2015 – From 2015



CAP From 2007

**PROCESSED AT :****Thyrocare**D-37/1, TTC MIDC, Turbhe,  
Navi Mumbai-400 703

Thyrocare Technologies Limited, D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400 703 | 9870666333 | wellness@thyrocare.com

***First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation<sup>#</sup>***

**NAME** : MANASA ANUPA (28Y/F)  
**REF. BY** : DR VISHWA BHARATHI MBBS DGO  
**TEST ASKED** : T3-T4-USTSH, QUADRUPLE MARKER SECOND TRIMESTER  
14-22 WEEK

**SAMPLE COLLECTED AT :**(5053270516), BHAVITHA LABORATORY, DR. MD  
SHANKAR LINE, OPP OLD SAI HOSPITAL,  
ARAVIND NAGAR, JAGTIAL, TELANGANA, 505327**Report Availability Summary****Note:** Please refer to the table below for status of your tests. **2** Ready **0** Ready with Cancellation **0** Processing **0** Cancelled in Lab**TEST DETAILS****REPORT STATUS****T3-T4-USTSH**

Ready

**QUADRUPLE MARKER SECOND TRIMESTER 14-22 WEEK**

Ready

PROCESSED AT :

Thyrocare

D-37/1, TTC MIDC, Turbhe,  
Navi Mumbai-400 703



Tests you can trust

Thyrocare Technologies Limited, D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400 703 | 9870666333 | wellness@thyrocare.com

**First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation<sup>#</sup>**

**NAME** : MANASA ANUPA (28Y/F)

**REF. BY** : DR VISHWA BHARATHI MBBS DGO

**TEST ASKED** : T3-T4-USTSH,QUADRUPLE MARKER SECOND TRIMESTER  
14-22 WEEK

**SAMPLE COLLECTED AT :**

(5053270516), BHAVITHA LABORATORY, DR. MD  
SHANKAR LINE, OPP OLD SAI HOSPITAL, ARAVIND  
NAGAR, JAGTIAL, TELANGANA, 505327

### Summary Report

#### Tests outside reference range

TEST NAME	OBSERVED VALUE	UNITS	Bio. Ref. Interval.
<b>THYROID</b>			
TOTAL THYROXINE (T4)	14	µg/dL	4.8-12.7
TOTAL TRIIODOTHYRONINE (T3)	208	ng/dL	80-200

**Disclaimer:** The above listed is the summary of the parameters with values outside the BRI. For detailed report values, parameter correlation and clinical interpretation, kindly refer to the same in subsequent pages.

PROCESSED AT :

Thyrocare

D-37/1, TTC MIDC, Turbhe,  
Navi Mumbai-400 703



Thyrocare Technologies Limited, D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400 703 | 9870666333 | wellness@thyrocare.com

First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation<sup>#</sup>

**NAME** : MANASA ANUPA (28Y/F)  
**REF. BY** : DR VISHWA BHARATHI MBBS DGO  
**TEST ASKED** : QUADRUPLE MARKER SECOND TRIMESTER 14-22 WEEK,T3-T4-USTSH

**SAMPLE COLLECTED AT :**  
(5053270516), BHAVITHA LABORATORY, DR. MD SHANKAR LINE, OPP OLD SAI HOSPITAL, ARAVIND NAGAR, JAGTIAL, TELANGANA, 505327

TEST NAME	TECHNOLOGY	VALUE	UNITS
INHIBIN A	C.L.I.A	267.1	pg/mL

**Bio. Ref. Interval. :-**

Normal cycling females (Days from LH surge)

Early Follicular Phase (-14 to -10)	1.8 - 17.3
Mid Follicular Phase (-9 to -4)	3.5 - 31.7
Late Follicular Phase (-3 to -1)	9.8 - 90.3
Mid cycle (Day 0, LH surge)	16.9- 91.8
Early Luteal Phase (1 to 3)	16.1- 97.5
Mid Luteal Phase (4 to 11)	3.9 - 87.7
Late Luteal Phase (12 to 14)	2.7 - 47.1

Postmenopausal females	< 1.0 - 2.1
Males	< 1.0 - 2

**Clinical Significance :**

Inhibin A level is used as an endocrine marker for androgen production and monitoring ovarian function. These levels are also used in maternal serum quadruple screening test, to estimate the chance of having birth defects in baby. Increased levels of Inhibin A are related to many conditions in placenta like infection, hypoxia and placental malformations.

Specifications: Precision: Intra assay (%CV): 4.17 %, Inter assay (%CV): 4.28%; Sensitivity: < 1 pg/mL.

Kit Validation References:

Burger HG Evidence for a negative feedback role of inhibin in folliclestimulating hormone regulation in women 1993;1-2:129-32

**Please correlate with clinical conditions.**

**Method:-** SEQUENTIAL TWO-STEP IMMUNOENZYMATIC (SANDWICH) ASSAY

**Sample Collected on (SCT)** : 13 Jan 2025 20:47  
**Sample Received on (SRT)** : 15 Jan 2025 01:20  
**Report Released on (RRT)** : 15 Jan 2025 18:41  
**Sample Type** : SERUM  
**Labcode** : 1401002947/A4564 Dr Renuka MD(Path)  
**Barcode** : CY002739

Dr Arshya MD(Path)

Page : 1 of 7

PROCESSED AT :

Thyrocare

D-37/1, TTC MIDC, Turbhe,  
Navi Mumbai-400 703



Thyrocare Technologies Limited, D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400 703 | 9870666333 | wellness@thyrocare.com

First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation<sup>#</sup>

**NAME** : MANASA ANUPA (28Y/F)  
**REF. BY** : DR VISHWA BHARATHI MBBS DGO  
**TEST ASKED** : QUADRUPLE MARKER SECOND TRIMESTER 14-22 WEEK,T3-T4-USTSH

**SAMPLE COLLECTED AT :**  
(5053270516), BHAVITHA LABORATORY, DR. MD SHANKAR LINE, OPP OLD SAI HOSPITAL, ARAVIND NAGAR, JAGTIAL, TELANGANA, 505327

TEST NAME	TECHNOLOGY	VALUE	UNITS
ALPHA FETO PROTEIN	E.C.L.I.A	23.7	IU/mL

**Bio. Ref. Interval :-**

Men: 0.5 - 5.5 IU/ml

Non-Pregnant Women: 0.5 - 5.5 IU/ml Pregnancy:

Week Range

14th : 10.41 - 49.40

15th : 13.11 - 57.08

16th : 15.12 - 64.45

17th : 17.72 - 76.11

18th : 19.26 - 91.51

19th : 23.26 - 101.80

20th : 28.05 - 125.85

21st : 33.30 - 92.75

Clinical Significance:

AFP has been used as a cancer marker. AFP testing during pregnancy in combination with Beta HCG and E3, is recommended as an effective way to determine potential fetal risk of open neural tube defect (NTD).

Specifications: Precision: Intra assay (%CV): 4.1, Inter assay (%CV): 4.2, Sensitivity: 1.5 IU/mL

References : Kaur G, Srivastav J, Sharma S, Huria A, Goel P, Chavan BS. Maternal serum median levels of alpha-foetoprotein, human chorionic gonadotropin & unconjugated estriol in second trimester in pregnant women from north-west India. Indian J Med Res. 2013;138(1):83-8.

**Please correlate with clinical conditions.**

**Method:-** SANDWICH ELECTROCHEMILUMINESCENCE IMMUNOASSAY

**Sample Collected on (SCT)** : 13 Jan 2025 20:47  
**Sample Received on (SRT)** : 15 Jan 2025 01:20  
**Report Released on (RRT)** : 15 Jan 2025 18:41  
**Sample Type** : SERUM  
**Labcode** : 1401002947/A4564 Dr Renuka MD(Path)  
**Barcode** : CY002739

Dr Arshya MD(Path)

Page : 2 of 7

PROCESSED AT :

Thyrocare

D-37/1, TTC MIDC, Turbhe,  
Navi Mumbai-400 703



Thyrocare Technologies Limited, D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400 703 | 9870666333 | wellness@thyrocare.com

First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation<sup>#</sup>

**NAME** : MANASA ANUPA (28Y/F)  
**REF. BY** : DR VISHWA BHARATHI MBBS DGO  
**TEST ASKED** : QUADRUPLE MARKER SECOND TRIMESTER 14-22 WEEK,T3-T4-USTSH

**SAMPLE COLLECTED AT :**  
(5053270516), BHAVITHA LABORATORY, DR. MD SHANKAR LINE, OPP OLD SAI HOSPITAL, ARAVIND NAGAR, JAGTIAL, TELANGANA, 505327

TEST NAME	TECHNOLOGY	VALUE	UNITS
BETA HCG	E.C.L.I.A	40360	mIU/mL

**Bio. Ref. Interval. :-**

Men : <2.6 mIU/mL Post menopausal women : <8.3 mIU/mL Non pregnant premenopausal women : <5.3 mIU/mL  
Weeks of gestation Ranges

Week	Range	Week	Range
3rd	5.8-71.2	10th	46509-186977
4th	9.5-750	12th	27832-210612
5th	217-7138	14th	13950-62530
6th	158-31795	15th	12039-70971
7th	3697-163563	16th	9040-56451
8th	32065-149571	17th	8175-55868
9th	63803-151410	18th	8099-58176

**Clinical Significance:** The rapid rise in HCG Serum levels after conception makes it an excellent marker for early confirmation and monitoring of pregnancy. HCG levels can be useful in prediction of spontaneous abortions, Aiding in the detection of ectopic pregnancy and multiple gestation. For diagnostic purpose, Results should always be assessed in conjunction with the patients medical history, clinical examination and other findings.

**Specifications:** Precision: Intra assay (%CV): 4.2, Inter assay (%CV): 6.3, Sensitivity: <= 0.200 mIU/mL

**Reference :** Schwarz S, Berger P, Wick G. The Antigenic Surface of Human Chorionic Gonadotropin as Mapped by Murine Monoclonal Antibodies.

Endocrinology 1986;118(1):189-197

**Please correlate with clinical conditions.**

**Method:-** SANDWICH ELECTROCHEMILUMINESCENCE IMMUNOASSAY

**Sample Collected on (SCT)** : 13 Jan 2025 20:47  
**Sample Received on (SRT)** : 15 Jan 2025 01:20  
**Report Released on (RRT)** : 15 Jan 2025 18:41  
**Sample Type** : SERUM  
**Labcode** : 1401002947/A4564 Dr Renuka MD(Path)  
**Barcode** : CY002739

Dr Arshya MD(Path)

Page : 3 of 7

PROCESSED AT :

Thyrocare

D-37/1, TTC MIDC, Turbhe,  
Navi Mumbai-400 703



Thyrocare Technologies Limited, D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400 703 | 9870666333 | wellness@thyrocare.com

First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation<sup>#</sup>

**NAME** : MANASA ANUPA (28Y/F)  
**REF. BY** : DR VISHWA BHARATHI MBBS DGO  
**TEST ASKED** : QUADRUPLE MARKER SECOND TRIMESTER 14-22 WEEK,T3-T4-USTSH

**SAMPLE COLLECTED AT :**  
(5053270516), BHAVITHA LABORATORY, DR. MD SHANKAR LINE, OPP OLD SAI HOSPITAL, ARAVIND NAGAR, JAGTIAL, TELANGANA, 505327

TEST NAME	TECHNOLOGY	VALUE	UNITS
UNCONJUGATED ESTRIOL - uE3	C.L.I.A	0.35	ng/mL

**Bio. Ref. Interval. :-**

Males and Non pregnant Females : < 2.0

Pregnancy:

Weeks	Ranges
16 Weeks	: 0.30-1.05
18 Weeks	: 0.63-2.30
34 weeks	: 5.3-18.3
35 Weeks	: 5.2 -26.4
36 Weeks	: 8.2-28.1
37 Weeks	: 8.0-30.1
38 Weeks	: 8.6-38.0
39 Weeks	: 7.2-34.3
40 Weeks	: 9.6-28.9

Clinical Significance :

There is considerable patient-to-patient variability: The reference range for a given gestational age may encompass Estriol levels from 50 to 200 percent of the median for that age. Hence the pattern generated by serial determination is of greater significance than the results of isolated measurements. Persistently low or rapidly falling Estriol levels suggest fetal distress. Estriol concentration are subject to diurnal and episodic variation; Please refer serum levels to a baseline, Defined for the patient as either the average or the highest of her three most recent Estriol results.

Specifications: Precision: Intra assay (%CV): 10.75, Inter assay (%CV): 6.15, Sensitivity: 0.017 ng/mL

Reference : Teetz Chapter 45

**Please correlate with clinical conditions.**

**Method:-** Competitive binding immunoenzymatic assay

**Sample Collected on (SCT)** : 13 Jan 2025 20:47  
**Sample Received on (SRT)** : 15 Jan 2025 01:20  
**Report Released on (RRT)** : 15 Jan 2025 18:41  
**Sample Type** : SERUM  
**Labcode** : 1401002947/A4564 Dr Renuka MD(Path)  
**Barcode** : CY002739

Dr Arshya MD(Path)

Page : 4 of 7

PROCESSED AT :

Thyrocare

D-37/1, TTC MIDC, Turbhe,  
Navi Mumbai-400 703



Thyrocare Technologies Limited, D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400 703 | 9870666333 | wellness@thyrocare.com

First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation#

NAME	: MANASA ANUPA (28Y/F)	SAMPLE COLLECTED AT :
REF. BY	: DR VISHWA BHARATHI MBBS DGO	(5053270516), BHAVITHA LABORATORY, DR. MD SHANKAR LINE, OPP OLD SAI HOSPITAL, ARAVIND NAGAR, JAGTIAL, TELANGANA, 505327
TEST ASKED	: QUADRUPLE MARKER SECOND TRIMESTER 14-22 WEEK, T3-T4-USTSH	

TEST NAME	TECHNOLOGY	VALUE	UNITS	Bio. Ref. Interval.
<b>TOTAL TRIIODOTHYRONINE (T3)</b>	<b>E.C.L.I.A</b>	<b>208</b>	<b>ng/dL</b>	<b>80-200</b>
<b>TOTAL THYROXINE (T4)</b>	<b>E.C.L.I.A</b>	<b>14</b>	<b>µg/dL</b>	<b>4.8-12.7</b>
TSH - ULTRASENSITIVE	E.C.L.I.A	2.12	µIU/mL	0.54-5.30

The Biological Reference Ranges is specific to the age group. Kindly correlate clinically.

Method :

T3, T4 - Fully Automated Electrochemiluminescence Competitive Immunoassay  
USTSH - Fully Automated Electrochemiluminescence Sandwich Immunoassay

Pregnancy reference ranges for TSH/USTSH :

Trimester || T3 (ng/dl) || T4 (µg/dl) || TSH/USTSH (µIU/ml)

1st	83.9-196.6	4.4-11.5	0.1-2.5
2nd	86.1-217.4	4.9-12.2	0.2-3.0
3rd	79.9-186	5.1-13.2	0.3-3.5

References :

1. Carol Devilia, C I Parhon. First Trimester Pregnancy ranges for Serum TSH and Thyroid Tumor reclassified as Benign. Acta Endocrinol. 2016; 12(2) : 242 - 243
2. Kulhari K, Negi R, Kalra DK et al. Establishing Trimester specific Reference ranges for thyroid hormones in Indian women with normal pregnancy : New light through old window. Indian Journal of Contemporary medical research. 2019; 6(4)

**Disclaimer :** Results should always be interpreted using the reference range provided by the laboratory that performed the test. Different laboratories do tests using different technologies, methods and using different reagents which may cause difference. In reference ranges and hence it is recommended to interpret result with assay specific reference ranges provided in the reports. To diagnose and monitor therapy doses, it is recommended to get tested every time at the same Laboratory.

<b>Sample Collected on (SCT)</b>	: 13 Jan 2025 20:47
<b>Sample Received on (SRT)</b>	: 15 Jan 2025 01:20
<b>Report Released on (RRT)</b>	: 15 Jan 2025 18:41
<b>Sample Type</b>	: SERUM
<b>Labcode</b>	: 1401002947/A4564
<b>Barcode</b>	: CY002739

Dr Renuka MD(Path)

Dr Arshiya MD(Path)

Page : 5 of 7

## Second Trimester Screening results

### Patient data

Name and surname:	MANASA ANUPA	Weight:	83 Kg.
Lab ID:	CY002739	Height:	N/I
Race/Ethnicity:	INDIAN	Diabetes:	No
Date of birth:	30-10-1996 (28 years in the DoB)	Smoker:	No
Type of Pregnancy:	Spontaneous	Ovulation Ind.:	No
Prev. Obstetric History:	None	Referral Center:	A4564
Prenatal Software:	SSDWLAB6	Referral Doctor:	DR VISHWA BHARATHI

### Biochemical data

Sample date:	13-01-2025	Gestational age:	14 weeks and 2 days
Sample ID:	CY002739		
Alpha-fetoprotein:	23.7 IU/ml	1.38 MoM	
hCG + beta:	40360 mIU/ml	1.35 MoM	
Unconjugated Oestriol:	0.35 ng/ml	0.58 MoM	
Inhibin-A:	267.1 pg/ml	1.87 MoM	

### Risk report (At term)

Risk type	Probability	Result	Graphic representation
NTD:	No	Low Risk	No
Trisomy 21 age risk:	1/1101		1/1101
Trisomy 21:	1/943	Low Risk	1/943 250
Trisomy 18/13:	1/31043	Low Risk	1/31043 250

### Observations

#### Low Risk.

NOTE: Second Trimester test uses assays for maternal serum alpha fetoprotein (AFP), Beta subunit of human chorionic gonadotropin (B-HCG), unconjugated estriol (uE3) for Triple test, and is Inhibin A is add for Quad test combined with patient specific data including patient age or weeks of pregnancy(WOP) weight, gestational age, number of fetus, previous bad obstetric history, medical history, information about IVF pregnancy, and demographics to calculate the numerical risk for fetal Down syndrome, Edward syndrome and neural tube defects. It uses a sophisticated software program called SsdwLab6, which works on a statistical database to calculate this risk, and hence any risk indicated should not be considered to be a confirmatory evidence of fetal risk. A risk indicated only says that further investigations are needed before a decision is taken and therefore the report should be interpreted in light of other clinical and laboratory evidences.

- The risk calculations are statistical approaches and have limited diagnostic value.
- The calculated risk by the software depends on the accuracy of USG details and patient details provided.
- Participants in UKAS-proficiency testing (EQAS) for maternal serum markers.
- The laboratory can not be held responsible for their impact on the risk assessment. Calculated risks have no diagnostic value.
- The screening risk estimates final risk using biochemical parameters results, maternal demographic characteristics, and maternal medical and obstetric history. The risk calculation is optimal when accurate critical information is provided and incorrect information ((TRF/ U.S scan report) may significantly alter the risk assessment.
- Risks cannot be calculated for triplets or higher order gestations. In twin pregnancies with fetal demise (vanishing twins) risk estimation can be calculated but may be unreliable.

**9 out of 10 Doctors Trust that Thyrocare Reports are Accurate & Reliable**

- Comparison with other screening software's and assay methodologies may give varying risk assessments. Risk assessment at term and sampling are both valid ways of estimating risk, but the risk score between the two varies because a correction factor of intrauterine mortality is applied for risk at sampling which is not taken into consideration while computing risk at term.
- Sophisticated software program SsdwLab6 works on statistical database to calculate this risk and hence any risk indicated should not be considered to be confirmatory evidence of fetal risk.
- This is a screening report and will need further confirmatory tests for diagnosis. Kindly consult your doctor for further.

Anomaly	Risk Ratio	Risk Categorization
Down's Syndrome (Trisomy 21)	> 1:250	Low Risk
	< 1:250	High Risk
Trisomy 13/18	> 1:250	Low Risk
	< 1:250	High Risk
NTD	No	Low Risk
	Yes	High Risk

**Authorized by:**

Adinath Suryavanshi

**Printing date:**

15-01-2025



 Dr. Arshiya Bose  
 MBBS, MD Pathology

## CONDITIONS OF REPORTING

- ✓ The reported results are for information and interpretation of the referring doctor only.
- ✓ It is presumed that the tests performed on the specimen belong to the patient; named or identified.
- ✓ Results of tests may vary from laboratory to laboratory and also in some parameters from time to time for the same patient.
- ✓ Should the results indicate an unexpected abnormality, the same should be reconfirmed.
- ✓ Only such medical professionals who understand reporting units, reference ranges and limitations of technologies should interpret results.
- ✓ This report is not valid for medico-legal purpose.
- ✓ Neither Thyrocare, nor its employees/representatives assume: (a) any liability, responsibility for any loss or damage that may be incurred by any person as a result of presuming the meaning or contents of the report, (b) any claims of any nature whatsoever arising from or relating to the performance of the requested tests as well as any claim for indirect, incidental or consequential damages. The total liability, in any case, of Thyrocare shall not exceed the total amount of invoice for the services provided and paid for.
- ✓ Thyrocare Discovery video link :- <https://youtu.be/nbdYeRgYyQc>

## EXPLANATIONS

- ✓ Majority of the specimen processed in the laboratory are collected by Pathologists and Hospitals we call them as "Clients".
- ✓ **Name** - The name is as declared by the client and recorded by the personnel who collected the specimen.
- ✓ **Ref.Dr** - The name of the doctor who has recommended testing as declared by the client.
- ✓ **Labcode** - This is the accession number in our laboratory and it helps us in archiving and retrieving the data.
- ✓ **Barcode** - This is the specimen identity number and it states that the results are for the specimen bearing the barcode (irrespective of the name).
- ✓ **SCP** - Specimen Collection Point - This is the location where the blood or specimen was collected as declared by the client.
- ✓ **SCT** - Specimen Collection Time - The time when specimen was collected as declared by the client.
- ✓ **SRT** - Specimen Receiving Time - This time when the specimen reached our laboratory.
- ✓ **RRT** - Report Releasing Time - The time when our pathologist has released the values for Reporting.
- ✓ **Reference Range** - Means the range of values in which 95% of the normal population would fall.

## SUGGESTIONS

- ✓ Values out of reference range requires reconfirmation before starting any medical treatment.
- ✓ Retesting is needed if you suspect any quality shortcomings.
- ✓ Testing or retesting should be done in accredited laboratories.
- ✓ For suggestions, complaints, clinical support or feedback, write to us at [customersupport@thyrocare.com](mailto:customersupport@thyrocare.com) or call us on **022-3090 0000**



Explore & Select Test / Profile



Book Through App




Booking Confirmation



Track your Technician



Blood Collection



Sample Testing



Download Report & Receipt

*Preventive Healthcare is now at your fingertips!*

Download Thyroapp Now



*Launching*

# Jaanch

*For a closer look at your health with*

**Doctor-Curated Specialised Packages All Under One Roof**

 Heart	 Fever	 Cancer	 Women's - Reproductive Health	
 Thyroid	 Diabetes	 STDs	 Skin Care	 Hair Fall



**Thyrocare**  
Tests you can trust

\*T&C Apply, #As on 5th December 2024, \*As per a survey on doctors' perception of laboratory diagnostics (IJARIIT,2023)

Page : 7 of 7